|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Hydralazine#Warnings]] |
| {{Hydralazine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| Myocardial stimulation produced by hydralazine can cause anginal attacks and ECG changes of [[myocardial ischemia]]. The drug has been implicated in the production of [[myocardial infarction]]. It must, therefore, be used with caution in patients with suspected [[coronary artery disease]].
| |
| | |
| The “hyperdynamic” circulation caused by hydralazine may accentuate specific cardiovascular inadequacies. For example, hydralazine may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine. [[Postural hypotension]] may result from hydralazine but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular accidents.
| |
| | |
| In hypertensive patients with normal kidneys who are treated with hydralazine, there is evidence of increased renal blood flow and a maintenance of [[glomerular filtration rate]]. In some instances where control values were below normal, improved renal function has been noted after administration of hydralazine. However, as with any antihypertensive agent, hydralazine should be used with caution in patients with advanced renal damage.
| |
| | |
| [[Peripheral neuritis]], evidenced by [[paresthesia]], [[numbness]], and [[tingling]], has been observed. Publishing evidence suggests an antipyridoxine effect and that [[pyridoxine ]]should be added to the regimen if symptoms develop.
| |
| | |
| ===Laboratory Tests===
| |
| Complete blood counts and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy with hydralazine even though the patient is asymptomatic. These studies are also indicated if the patient develops [[arthralgia]], [[fever]], [[chest pain]], continued malaise or other unexplained signs or symptoms.
| |
| | |
| A positive [[antinuclear antibody]] titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine hydrochloride.
| |
| | |
| Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, [[leukopenia]], [[agranulocytosis]], and [[purpura]], have been reported. If such abnormalities develop, therapy should be discontinued.
| |
| | |
| ===Drug Interactions===
| |
| [[MAO inhibitors]] should be used with caution in patients receiving hydralazine.
| |
| | |
| When other potent parenteral antihypertensive drugs, such as [[diazoxide]], are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when [[diazoxide ]]injection and hydralazine hydrochloride injection are used concomitantly.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |